Alerts will be sent to your verified email
Verify EmailUNICHEMLAB
|
Unichem Lab
|
Gufic Biosciences
|
Panacea Biotec
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
41.0 . | n/a | 6.0 . |
|
Number of ANDA's Approved By USFDA
|
27.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
5.35 % | 1.28 % | 9.86 % |
|
Financials
|
|||
|
5 yr Average ROE
|
-0.79 % | 16.89 % | 36.5 % |
|
5yr average Equity Multiplier
|
1.32 | 2.16 | 0.36 |
|
5yr Average Asset Turnover Ratio
|
0.47 | 0.75 | 0.41 |
|
5yr Avg Net Profit Margin
|
-1.68 % | 10.24 % | 26.1 % |
|
Price to Book
|
1.24 | 4.91 | 2.74 |
|
P/E
|
10.27 | 54.41 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
88.84 Days | -15.25 Days | -170.26 Days |
|
Inventory Days
|
151.32 Days | 71.73 Days | 120.03 Days |
|
Days Receivable
|
122.86 Days | 106.89 Days | 42.2 Days |
|
Days Payable
|
205.05 Days | 179.29 Days | 325.14 Days |
|
5yr Average Interest Coverage Ratio
|
2.41 | 8.9 | 2.7 |
|
5yr Avg ROCE
|
1.04 % | 17.89 % | -2.79 % |
|
5yr Avg Operating Profit Margin
|
5.43 % | 18.12 % | -3.85 % |
|
5 yr average Debt to Equity
|
0.11 | 0.67 | -0.69 |
|
5yr CAGR Net Profit
|
32.0 % | -2.66 % | -43.68 % |
|
5yr Average Return on Assets
|
-0.65 % | 7.7 % | 9.32 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
70.22 % | 72.5 % | 72.48 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
19.29 % | -2.5 % | -1.11 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
2.39 % | 2.5 % | 0.0 |
|
Unichem Lab
|
Gufic Biosciences
|
Panacea Biotec
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|